BOIRF logo

Boiron S.A. (BOIRF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Cotizando a $, Boiron S.A. (BOIRF) es una empresa del sector Healthcare valorada en 0. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 17 mar 2026
Puntuación de IA de 43/100

Boiron S.A. (BOIRF) Resumen de Asistencia Médica y Tuberías

CEOThierry Boiron
Empleados2469
Sede CentralMessimy, FR
Año de la oferta pública inicial (OPI)1996

Boiron S.A. specializes in the manufacture and sale of homeopathic medicines, with a strong market presence in Europe and North America, and a diverse product portfolio that addresses various health concerns, from flu symptoms to anxiety disorders.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 17 mar 2026

Tesis de Inversión

Boiron S.A. presents a compelling case for growth in the homeopathic medicine sector, driven by increasing consumer interest in natural and alternative therapies. The company's market capitalization of $0.52 billion and a P/E ratio of 23.17 indicate a stable financial position, while a gross margin of 73.7% reflects efficient operations. Key growth catalysts include the rising demand for homeopathic remedies, particularly in North America, where awareness of alternative medicine is growing. Additionally, Boiron's established brand reputation and diverse product range position it well to capture market share in an expanding healthcare landscape. However, potential risks include regulatory changes affecting homeopathic products and competition from both traditional pharmaceuticals and other alternative medicine providers. Overall, Boiron's strategic focus on innovation and customer engagement will be crucial for sustaining growth in the coming years.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market Cap of $0.52B indicates a solid position in the homeopathic sector.
  • P/E ratio of 23.17 suggests a stable valuation relative to earnings.
  • Profit margin of 3.8% reflects the company's operational efficiency.
  • Gross margin of 73.7% exceeds industry averages, indicating strong pricing power.
  • Dividend yield of 4.64% provides a return to shareholders amidst growth.

Competidores y Pares

Fortalezas

  • Strong brand reputation in homeopathy.
  • Diverse product offerings across various health categories.
  • High gross margin indicating operational efficiency.
  • Established distribution channels enhancing market reach.

Debilidades

  • Limited presence in rapidly growing international markets.
  • Dependence on the homeopathic segment, which may face regulatory scrutiny.
  • Relatively low profit margins compared to larger pharmaceutical companies.
  • Potential challenges in scaling production for new product lines.

Catalizadores

  • Upcoming: Expansion into North American markets to capture growing demand for homeopathic products.
  • Ongoing: Continued investment in research and development to innovate and diversify product offerings.
  • Ongoing: Strengthening of digital marketing strategies to enhance online sales and brand visibility.
  • Upcoming: Introduction of new product lines targeting emerging health trends.
  • Ongoing: Active engagement with regulatory bodies to navigate potential changes in the homeopathic sector.

Riesgos

  • Potential: Regulatory changes that could impact the sale and marketing of homeopathic products.
  • Ongoing: Competition from both traditional pharmaceuticals and other alternative medicine providers.
  • Potential: Market volatility affecting consumer spending on healthcare products.
  • Ongoing: Challenges in scaling production for new product lines amid increasing demand.

Oportunidades de crecimiento

  • Expansion in North America: Boiron S.A. aims to increase its market presence in North America, where the demand for homeopathic products is on the rise. The North American homeopathy market is expected to grow significantly, driven by increasing consumer awareness and preference for natural remedies. By enhancing distribution channels and marketing efforts, Boiron can capture a larger share of this lucrative market within the next five years.
  • Product Line Diversification: Boiron plans to expand its product offerings to include new homeopathic remedies and dietary supplements. This diversification strategy targets emerging health trends, such as immunity support and mental wellness, which are gaining traction among consumers. With the global dietary supplement market projected to reach $230 billion by 2027, Boiron's entry into this space could significantly enhance revenue streams.
  • Digital Transformation: The company is investing in digital marketing and e-commerce platforms to reach a broader audience. As online sales of health products continue to rise, Boiron's focus on enhancing its digital presence could lead to increased sales and brand loyalty. This initiative aligns with the growing trend of consumers purchasing health products online, especially post-pandemic.
  • International Market Penetration: Boiron seeks to penetrate untapped international markets, particularly in Asia and Latin America, where the demand for alternative medicine is growing. By establishing partnerships with local distributors and adapting products to meet regional preferences, Boiron can leverage new revenue opportunities in these emerging markets over the next few years.
  • Research and Development: Continued investment in R&D will enable Boiron to innovate and develop new homeopathic formulations. As consumer preferences shift towards personalized medicine, Boiron's commitment to research can position it as a leader in the homeopathic space, potentially increasing market share and enhancing product efficacy.

Oportunidades

  • Growing consumer interest in natural and alternative health products.
  • Expansion into emerging markets with increasing demand for homeopathy.
  • Digital transformation to enhance online sales and marketing.
  • Research and development for innovative product formulations.

Amenazas

  • Regulatory changes impacting the homeopathic industry.
  • Intense competition from both traditional pharmaceuticals and alternative medicine providers.
  • Market volatility affecting consumer spending on healthcare products.
  • Potential negative perceptions of homeopathy among some healthcare professionals.

Ventajas competitivas

  • Established brand recognition in the homeopathic market.
  • Strong product portfolio with a focus on quality and efficacy.
  • Commitment to research and development for continuous innovation.
  • Diverse distribution channels providing broad market access.
  • Expertise in homeopathy, enhancing credibility and trust among consumers.

Acerca de BOIRF

Founded in 1932 and headquartered in Messimy, France, Boiron S.A. has established itself as a prominent manufacturer and distributor of homeopathic medicines. The company began its journey with a commitment to providing natural remedies and has evolved into a leader in the homeopathy sector, offering both proprietary and non-proprietary products. Boiron's extensive range includes well-known brands such as Oscillococcinum, which is used for flu-like symptoms, and Sédatif PC, aimed at alleviating anxiety and sleep disorders. The company also produces a variety of herbal medicines and dietary supplements, catering to diverse health needs. Boiron's distribution network spans pharmacies, grocery stores, health food outlets, and online platforms, enabling it to reach a broad customer base across France, Europe, North America, and beyond. With a workforce of approximately 2,469 employees, Boiron continues to innovate and expand its product offerings, maintaining a strong commitment to the principles of homeopathy and natural health.

Qué hacen

  • Manufacture and sell homeopathic medicines globally.
  • Offer a wide range of branded homeopathic products for various health issues.
  • Provide dietary supplements and herbal medicines.
  • Develop medical devices, including COVID self-tests.
  • Distribute products through pharmacies, health food stores, and online retail.
  • Focus on innovation and quality in homeopathic formulations.

Modelo de Negocio

  • Generate revenue through the sale of homeopathic and herbal medicines.
  • Leverage a diverse product portfolio to cater to various health needs.
  • Utilize a multi-channel distribution strategy to reach consumers effectively.
  • Invest in research and development to innovate and expand product offerings.
  • Engage in marketing initiatives to enhance brand awareness and customer loyalty.

Contexto de la Industria

The drug manufacturing industry, particularly the specialty and generic segment, is witnessing significant growth, driven by increasing consumer preference for natural and homeopathic treatments. The global homeopathy market is projected to expand at a CAGR of approximately 15% over the next five years, fueled by rising awareness of alternative medicine and the growing prevalence of chronic diseases. Boiron S.A. is well-positioned within this landscape, leveraging its established brand and diverse product offerings to compete against both traditional pharmaceutical companies and other homeopathic providers. The competitive landscape includes peers such as AGYTF, BJTRF, CLVSF, ELTP, and GLASF, all of which are vying for market share in this evolving sector.

Clientes Clave

  • Pharmacies and pharmacy chains across Europe and North America.
  • Health food stores and grocery outlets.
  • Online consumers seeking natural health products.
  • Healthcare professionals recommending homeopathic remedies.
  • Parents looking for safe treatments for children.
Confianza de la IA: 72% Actualizado: 17 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Boiron S.A. (BOIRF): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para BOIRF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para BOIRF.

MoonshotScore

43/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de BOIRF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Thierry Boiron

CEO

Thierry Boiron has been instrumental in leading Boiron S.A. since its inception. With a strong background in homeopathy and healthcare management, he has dedicated his career to promoting natural remedies. Under his leadership, the company has expanded its product offerings and strengthened its market position in the homeopathic sector.

Historial: Thierry has successfully guided Boiron through various market challenges, enhancing brand recognition and driving international expansion. His strategic focus on innovation has resulted in the introduction of several new products that align with consumer health trends.

Información del mercado OTC de BOIRF

The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ. These stocks may have less stringent reporting requirements and can be less liquid, often resulting in wider bid-ask spreads. Investors should be aware of the potential for lower trading volumes and increased volatility.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Boiron S.A. may experience lower trading volumes due to its OTC classification, which can lead to wider bid-ask spreads. Investors may want to evaluate the potential difficulty in executing trades without impacting the stock price, especially during periods of low market activity.
Factores de riesgo OTC:
  • Lower liquidity compared to stocks listed on major exchanges, which can affect trading.
  • Increased volatility due to limited analyst coverage and market interest.
  • Potential for less transparency in financial reporting and disclosures.
  • Regulatory risks associated with the homeopathic sector.
Lista de verificación de diligencia debida:
  • Review available financial reports and earnings releases.
  • Assess the company's competitive positioning and market trends.
  • Monitor regulatory developments affecting homeopathic products.
  • Evaluate management's track record and strategic vision.
  • Investigate market sentiment and analyst opinions.
Señales de legitimidad:
  • Established brand presence in the homeopathic market since 1932.
  • Comprehensive product portfolio with a focus on quality.
  • Positive consumer feedback and brand loyalty in target markets.

BOIRF Preguntas Frecuentes sobre Acciones de Healthcare

¿Cuáles son los factores clave para evaluar BOIRF?

Boiron S.A. (BOIRF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Strong brand reputation in homeopathy.. Riesgo principal a monitorear: Potential: Regulatory changes that could impact the sale and marketing of homeopathic products.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de BOIRF?

BOIRF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de BOIRF?

Los precios de BOIRF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre BOIRF?

La cobertura de analistas para BOIRF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en BOIRF?

Las categorías de riesgo para BOIRF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes that could impact the sale and marketing of homeopathic products.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de BOIRF?

La relación P/E para BOIRF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está BOIRF sobrevalorada o infravalorada?

Determinar si Boiron S.A. (BOIRF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de BOIRF?

Boiron S.A. (BOIRF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Data sourced from company reports and market analysis. Financial metrics are subject to change based on market conditions.
Fuentes de datos

Popular Stocks